News | April 19, 2012

St. Jude Medical Launches New Trifecta Heart Valve in Japan

April 19, 2012 - St. Jude Medical Inc., a global medical device company, announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) and the launch of the Trifecta aortic stented, pericardial tissue valve. The first procedures in Japan were performed at Osaka University Hospital and Saitama Medical University International Medical Center.

For more than 30 years, St. Jude Medical has offered patients the gold standard in heart valve performance and tissue valve durability. The Trifecta valve is the company’s newest tissue valve for cardiac surgeons, and is clinically proven for patients with diseased, damaged or malfunctioning aortic heart valves. The next-generation tissue valve has a tri-leaflet stented pericardial design that offers excellent hemodynamic performance and long-term durability.

"The Trifecta valve is redefining the standard in cardiac surgery for tissue valves in its ability to improve patients’ quality of life, and I am pleased it is now available in Japan,” said Prof. Yoshiki Sawa M.D. of Cardiovascular Surgery at Osaka University Hospital. “The smaller valve is more suitable for Japanese patients, and also offers exceptional hemodynamic performance, which allows it to perform more like a natural heart valve.”

“The construction and design of the Trifecta valve enable it to work seamlessly with the patient’s heart to generate superior blood flow, which can offer patients an improved quality of life. I foresee that the number of patients with aortic valve diseases will continue increasing, and believe that those patients who are implanted with Trifecta will benefit from its performance,” said Prof. Hiroshi Niinami, M.D., of Cardiovascular Surgery at Saitama Medical University International Medical Center.

The valve is constructed using a polyester and tissue-covered, fatigue resistant, high strength titanium stent to ensure structural integrity of the valve. The valve features leaflets manufactured from pericardial tissue attached to the exterior of the valve stent. This design allows the leaflets to open more fully and efficiently, mimicking the performance of a healthy aortic heart valve, while also mitigating tissue abrasion through tissue-to-tissue (stent-to-leaflet) contact. Also contributing to durability is the St. Jude Medical patented Linx AC Technology, a proprietary anti-calcification treatment designed to reduce tissue mineralization (hardening), one of the primary causes of valve deterioration.

“The launch of the Trifecta valve marks an important milestone for patients with aortic heart valve disease, and we are pleased to provide it to leading hospitals throughout the country,” said William Phillips, president of St. Jude Medical Japan. “The Trifecta valve continues our legacy of market-leading valves and reflects our commitment to providing products that improve physician control, reduce patient risk and improve patient outcomes in Japan.”

The Trifecta valve is available in a wide range of sizes to offer physicians more control in choosing the appropriate replacement valve for each patient’s heart. The Trifecta stented tissue valve further expands the St. Jude Medical valve product portfolio, which includes market-leading mechanical heart valves, valve annuloplasty rings and porcine tissue valves with superior durability for both the aortic and mitral valve.

Symptoms of valve disease vary, but can include shortness of breath, dizziness, chest pain, or palpitations. Untreated aortic valve disease can eventually result in heart failure, severe infection, or sudden death. About two percent of the population over the age of 65 is estimated to have aortic stenosis.

For more information:

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery| September 08, 2017
September 8, 2017 — ClearFlow Inc.
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Protembis Announces Successful First-in-Human Use of  ProtEmbo Cerebral Protection System in European Trial
News | Embolic Protection Devices| September 07, 2017
Protembis GmbH announced the first clinical applications of its ProtEmbo Cerebral Protection System to complement a...
Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial
News | Heart Valve Technology| September 05, 2017
Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to...
World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy
News | Heart Valve Technology| August 31, 2017
NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent...
Overlay Init